FDA approval summary: Pertuzumab for adjuvant treatment of HER2-positive early breast cancer

Lynn J. Howie, Nancy S. Scher, Laleh Amiri-Kordestani, Lijun Zhang, Bellinda L. King-Kallimanis, Yasmin Choudhry, Jason Schroeder, Kirsten B. Goldberg, Paul G. Kluetz, Amna Ibrahim, Rajeshwari Sridhara, Gideon M. Blumenthal, Richard Pazdur, Julia A. Beaver

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Fingerprint

Dive into the research topics of 'FDA approval summary: Pertuzumab for adjuvant treatment of HER2-positive early breast cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences